A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

NCT05934955 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-11-08

No results posted yet for this study

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1839100 in healthy male subjects following oral administration of single rising doses.

Conditions

  • Healthy

Interventions

DRUG

BI 1839100

BI 1839100

DRUG

Placebo matching BI 1839100

Placebo matching BI 1839100

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-13
Primary Completion
2023-09-25
Completion
2023-10-02

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05934955 on ClinicalTrials.gov